BIOMAT Database Logo BIOMAT Database Logo

Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. 2008

M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O.Box 9101, 6500 HB Nijmegen, The Netherlands. M.Vonk@reuma.umcn.nl

OBJECTIVE Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity and a reduced life expectancy, especially in patients with rapidly progressive diffuse cutaneous SSc. As no proven treatment exists, autologous haematopoietic stem cell transplantation (HSCT) is employed as a new therapeutic strategy in patients with a poor prognosis. This study reports the effects on survival, skin and major organ function of HSCT in patients with severe diffuse cutaneous SSc. METHODS A total of 26 patients were evaluated. Peripheral blood stem cells were collected using cyclophosphamide (4 g/m2) and rHu G-CSF (5 to 10 microg/kg/day) and were reinfused after positive CD34+ selection. For conditioning, cyclophosphamide 200 mg/kg was used. RESULTS After a median follow-up of 5.3 (1-7.5) years, 81% (n = 21/26) of the patients demonstrated a clinically beneficial response. The Kaplan-Meier estimated survival at 5 years was 96.2% (95% CI 89-100%) and at 7 years 84.8% (95% CI 70.2-100%) and event-free survival, defined as survival without mortality, relapse or progression of SSc, resulting in major organ dysfunction was 64.3% (95% CI 47.9-86%) at 5 years and 57.1% (95% CI 39.3-83%) at 7 years. CONCLUSIONS This study confirms that autologous HSCT in selected patients with severe diffuse cutaneous SSc results in sustained improvement of skin thickening and stabilisation of organ function up to 7 years after transplantation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009017 Morbidity The proportion of patients with a particular disease during a given year per given unit of population. Morbidities
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.
August 2022, Rheumatology (Oxford, England),
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus.
December 2013, Clinical rheumatology,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis.
September 2008, Clinical rheumatology,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study.
August 2020, Annals of the rheumatic diseases,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis.
June 2023, Journal of scleroderma and related disorders,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.
November 2016, Rheumatology international,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis.
April 2012, QJM : monthly journal of the Association of Physicians,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy.
September 2018, Modern rheumatology,
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
May 2024, Multiple sclerosis (Houndmills, Basingstoke, England),
M C Vonk, and Z Marjanovic, and F H J van den Hoogen, and S Zohar, and A V M B Schattenberg, and W E Fibbe, and J Larghero, and E Gluckman, and F W M B Preijers, and A P J van Dijk, and J J Bax, and P Roblot, and P L C M van Riel, and J M van Laar, and D Farge
Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease.
December 2011, Journal of Crohn's & colitis,
Copied contents to your clipboard!